Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03519984
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:23.214766+00:00
Published At
2021-11-30T00:00:00+00:00
Record Updated At
2021-11-30
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Blasts 5 Percent or More of Bone Marrow Nucleated Cells", "Myelodysplastic/Myeloproliferative Neoplasm", "Philadelphia Chromosome Positive", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Secondary Acute Myeloid Leukemia", "T Acute Lymphoblastic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-11-30"
protocolSection.identificationModule.nctId
"NCT03519984"
protocolSection.identificationModule.officialTitle
"A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Blasts 5 Percent or More of Bone Marrow Nucleated Cells (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Philadelphia Chromosome Positive (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Secondary Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • T Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.